Jnj-98768111

Phase 1

Johnson & Johnson

Jnj-98768111 is one of 10 therapeutic programs targeting Prostatic Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostatic NeoplasmsRecruiting

Prostatic NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Prostatic Neoplasms

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

9 2

Zytiga

Johnson & Johnson

Phase 3

6 3

Xtandi

Astellas

Phase 3

3 4

Verzenio

Eli Lilly

Phase 3

2 5

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

3 6

Prednisone or Prednisolone

Johnson & Johnson

Phase 3

1 7

Trelstar

Jnj-101556143

3 9

JNJ-78278343

Johnson & Johnson

Phase 1

4 10

Jnj-98768111

Johnson & Johnson

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Prostatic Neoplasms

NCT07746713

Clinical

Trials by Indication[1]

Prostatic Neoplasms1 trial

A Phase 1 Trial of JNJ-98768111, an Antibody Drug Conjugate (ADC) Targeting Human Kallikrein-2 (KLK2) for Advanced Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07746713·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Jnj-98768111. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Jnj-98768111. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Johnson & Johnson

Jnj-98768111

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News